

Press release / Bern, 29 June 2026

Robert Bing Prize 2026 goes to Eduardo Martin Moraud, EPFL, and to Aiman S. Saab, UZH

The Robert Bing Prize 2026 is awarded to two outstanding neuroscientists: Eduardo Martin Moraud, assistant professor at EPFL, is being distinguished for his translational research on movement disorders, notably in relation to Parkinson's disease. Aiman S. Saab, professor at the University of Zurich, is honored for his fundamental contributions to understanding how glial cells help maintain neuronal and brain function. Each prize is worth 30'000 francs.

The Prize, bestowed every two years by the Swiss Academy of Medical Sciences (SAMS), originates from a generous bequest of Basel neurologist Robert Bing (1878–1956). In accordance with the donor's will, the Prize is awarded to researchers who have done outstanding work to improve the recognition, treatment and cure of neurological diseases. The award ceremony will take place on 12 November 2026 in Bern. Further information and an overview of past Bing Prize laureates are available on the SAMS website: sams.ch/bing-prize.

Prof. Eduardo Martin Moraud



Eduardo Martin Moraud is an assistant professor and the Medtronic Chair in Adaptive Neuromodulation at EPFL's Neuro X Institute. His translational research – at the intersection of clinical neurology, neuroscience and engineering – is advancing the development of closed-loop neuromodulation therapies to restore mobility in people with neurological disorders. Prof. Moraud's work is impressively broad, combining several disciplines and building on his multi-faceted expertise.

Eduardo Martin Moraud and his team have pioneered a promising approach in adaptive deep brain stimulation specifically designed to restore gait and balance in people with Parkinson's disease. Using personalized neural decoding algorithms, stimulation is adapted in real time to each patient's mobility demands and physiological state. In a first proof-of-concept clinical study, this approach demonstrated significant improvements in mobility. A key strength is its flexibility: Depending on the patient's needs, different motor symptoms associated with advanced Parkinson's disease can be targeted.

Eduardo Martin Moraud studied electrical and control engineering at Universidad Politécnica Madrid and at École des Mines in Paris, before obtaining a Master's degree in Artificial Intelligence from the University of Edinburgh. He earned a PhD in Neuroengineering from ETH Zurich in 2014 and subsequently conducted postdoctoral research at the University of Oxford. Before joining EPFL, he established his own research group at the Department of Clinical Neurosciences at CHUV. He has received several highly competitive fellowships, including a Marie Skłodowska-Curie Postdoctoral Fellowship as well as an Ambizione Fellowship and a Starting Grant from the Swiss National Science Foundation (SNSF).

Prof. Aiman S. Saab



Aiman S. Saab is a molecular neuroscientist and Associate Professor of Neuroglial Pharmacology at the University of Zurich. He and his group investigate the interplay of glial cells and neurons, with a particular focus on axons. A central goal of his internationally recognized research program is to better understand the mechanisms that contribute to maintaining brain function.

Prof. Saab and his team have significantly advanced our understanding of the metabolic coupling between glial cells and neurons, an exchange of metabolic products that is essential for maintaining neuronal function.

His groundbreaking work has far-reaching implications. It provides insights into brain aging and forms a strong basis for future advances in the treatment of neurological diseases, including age-related neurodegenerative disorders and multiple sclerosis. Aiman S. Saab has also pioneered methodological approaches, particularly combining electrophysiology and metabolic imaging. His lab has developed state-of-the-art procedures to study energy metabolism and cellular function in the nervous system.

Aiman S. Saab studied Medicine and Human Biology at Philipps-Universität Marburg. In 2012, he obtained a PhD in Neurobiology at Saarland University, Homburg, and afterwards held postdoctoral fellowships at the Max Planck Institute of Experimental Medicine in Göttingen and at the University of Zurich. Since 2018, Aiman S. Saab has been leading his own research group at the Institute of Pharmacology and Toxicology at UZH, from 2020 to 2025 as an SNSF Eccellenza Professor. In 2024, he was awarded an SNSF Consolidator Grant.

Contact

Tobias Hurth, Department Science | +41 31 306 92 94 | t.hurth@samw.ch

Portraits in print quality can be downloaded from the SAMS website: sams.ch/media.